Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...
News Medical on MSN7d
Heart medication may slow the progression of Huntington's diseaseResearch indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 ...
William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating today.Pick the best stocks and ...
A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa ...
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License ...
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on QURE stock, giving a Buy rating today.Pick the best stocks and ...
Study finds β-blockers may delay onset and slow progression of Huntington's disease, offering potential as a therapeutic strategy Study: β-Blocker Use and Delayed Onset and Progression of ...
The first patient has begun treatment on a global trial of a novel medication for Huntington's disease, led within the UK by ...
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the fatal illness. Huntington’s is an inherited condition that is caused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback